1T3.F Syndax Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
8.51 EUR
Close of Nov 12, 2026
8.32 21.66
Market cap
EUR 766M
P/E
-
P/B
76.68x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 1T3.F undervalued?

Graham number

The Graham number of Syndax Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Syndax Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Syndax Pharmaceuticals Inc yet.

Syndax Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid le…

Full company profile